跳至主要内容
临床试验/NCT02262364
NCT02262364已完成1 期

A Pilot Study of a Single Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis

Zimmer Biomet2 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2014年11月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
Zimmer Biomet
入组人数
11
试验地点
2
主要终点
Adverse Events

研究概览

简要总结

The primary objective of this study is to assess the safety of a single injection of APS.

详细描述

The primary objective of this study is to assess the safety of a single injection of APS in patients with painful unilateral knee osteoarthritis and who have not been able to get satisfactory pain relief with other treatments through one-month post treatment and monitor subjects for adverse events through 12 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female ≥40 and ≤75 years old at time of injection..
  • A standing radiograph of the knee showing a Kellgren-Lawrence grade of 2 to 4 (within 6 months of screening).
  • Body mass index ≤40 kg/m
  • A Western Ontario and McMaster Universities osteoarthritis index using the Likert scale, Version
  • (WOMAC LK 3.1) pain subscale total score ≥ 10 and ≤
  • Has undergone at least two prior conservative OA therapies without satisfactory pain relief.
  • Patient has failed to get satisfactory pain relief from either HA or steroid injections or would be considered an appropriate patient to receive either HA or steroid injections

排除标准

  • Presence of active infection or abnormal effusion in the knee immediately preceding treatment injection.
  • Presence of symptomatic OA in the non-study knee
  • Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, chondromalacia, arthritis secondary to other inflammatory diseases, or of metabolic origin; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, villonodular synovitis, and other non-OA joint disease.
  • Disease of spine, hip or other lower extremity joints of sufficient degree to affect assessment of the index knee
  • Untreated symptomatic injury of index knee (e.g., acute traumatic injury, anterior cruciate ligament injury, meniscus injury, cartilage lesion).
  • Knee radiographs showing bone-on-bone or other gross cartilage deficits.
  • Presence of surgical hardware or other foreign body in the index knee.
  • Intra-articular steroid injections in the index knee within 3 months of screening.
  • Intra-articular HA in the index knee within 6 months of screening.
  • Other intra-articular therapy in the index knee within 6 months prior to screening.
  • Systemic steroid use within 2 weeks of screening.
  • Planned/anticipated surgery of the index knee during the study period.
  • A history of local anesthetic allergy
  • Use of systemic immunosuppressants within six weeks of treatment.
  • Currently on anticoagulant therapy
  • Any documented clinically significant condition (e.g., diabetes, malignancy), finding, or psychiatric illness at screening which could compromise patient safety or interfere with the assessment of the safety and treatment effects of the study injection.
  • Skin breakdown at the index knee where the injection is planned to take place.
  • Pregnant or nursing mothers or women who are planning on getting pregnant during the time they will be participating in the study.
  • Known drug or alcohol dependence currently or within the last year.
  • Used any investigational drug or device within 30 days prior to screening.
  • Used any investigational biologic within 60 days prior to screening

研究组 & 干预措施

NStride APS

Experimental

Subjects will receive an intra-articular injection of APS.

干预措施: APS (Biological)

结局指标

主要结局

Adverse Events

时间窗: 1 Year

Adverse Events and Serious Adverse Events

次要结局

  • Change From Baseline to 12 Months in Pain, Stiffness, and Function in Daily Living Measured With WOMAC Questionnaire(12 months)
  • Change From Baseline to 12 Months in Pain as Measured by the Numeric Rating Scale (NRS)(12 months)
  • Change From Baseline to 12 Months in Pain as Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS)(12 months)

研究者

发起方
Zimmer Biomet
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验